CINECA IRIS Institutional Research Information System

PENNA, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.597
EU - Europa 2.639
AS - Asia 2.504
SA - Sud America 163
OC - Oceania 157
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 9
Totale 11.110
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.458
CN - Cina 1.128
IT - Italia 728
SG - Singapore 388
IE - Irlanda 361
JP - Giappone 293
DE - Germania 232
FR - Francia 219
SE - Svezia 179
KR - Corea 177
GB - Regno Unito 159
AU - Australia 149
FI - Finlandia 148
VN - Vietnam 136
BR - Brasile 132
TW - Taiwan 123
CA - Canada 119
ES - Italia 94
PL - Polonia 94
UA - Ucraina 94
ID - Indonesia 70
HK - Hong Kong 59
BE - Belgio 56
IN - India 53
NL - Olanda 52
DK - Danimarca 35
CH - Svizzera 30
PT - Portogallo 29
RU - Federazione Russa 28
TR - Turchia 24
GR - Grecia 23
NO - Norvegia 23
MX - Messico 19
AT - Austria 18
CO - Colombia 12
ET - Etiopia 12
TH - Thailandia 12
HU - Ungheria 10
EU - Europa 8
IR - Iran 8
NZ - Nuova Zelanda 8
AR - Argentina 7
CL - Cile 7
IL - Israele 7
NG - Nigeria 6
CZ - Repubblica Ceca 5
MY - Malesia 5
RO - Romania 5
ZA - Sudafrica 5
BD - Bangladesh 4
DZ - Algeria 4
LT - Lituania 4
MO - Macao, regione amministrativa speciale della Cina 3
RS - Serbia 3
SA - Arabia Saudita 3
SI - Slovenia 3
VE - Venezuela 3
BG - Bulgaria 2
BW - Botswana 2
EE - Estonia 2
KE - Kenya 2
MA - Marocco 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
PK - Pakistan 2
SN - Senegal 2
ZM - Zambia 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
EG - Egitto 1
GH - Ghana 1
IM - Isola di Man 1
IQ - Iraq 1
KZ - Kazakistan 1
LV - Lettonia 1
MD - Moldavia 1
NE - Niger 1
PS - Palestinian Territory 1
Totale 11.110
Salva come PNG Salva come JPEG
Città #
Santa Clara 564
Fairfield 453
Houston 360
Chandler 355
Dublin 343
Beijing 315
Singapore 307
Ashburn 234
Seattle 200
Woodbridge 196
Cambridge 184
Torino 181
Wilmington 181
Ann Arbor 166
Redwood City 141
Shanghai 134
Pisa 124
Columbus 102
Villeurbanne 95
Medford 90
Princeton 90
Warsaw 78
Nyköping 76
Turin 75
Jacksonville 72
Dong Ket 66
Jakarta 61
Taipei 61
Tokyo 57
Guangzhou 56
Nanjing 53
San Diego 45
Boston 35
Sydney 34
Dearborn 33
Seoul 32
Chengdu 31
Melbourne 31
Milan 31
Toronto 30
São Paulo 29
Barcelona 28
Wuhan 27
Phoenix 26
Rome 26
Jinan 25
Munich 25
Brisbane 24
Columbia 24
Hangzhou 22
Shenyang 22
Hefei 21
Helsinki 21
New York 20
Norwalk 20
Brussels 19
Hong Kong 19
London 19
Los Angeles 19
Chongqing 18
Madrid 18
Silver Spring 17
Chicago 16
Copenhagen 16
Duncan 16
Evanston 16
Berlin 15
Gainesville 15
Indianapolis 15
Londrina 15
Boardman 14
Dallas 14
Hanoi 14
Ottawa 14
Kyoto 13
Xian 13
Montréal 12
Nanchang 12
Oslo 12
Padova 12
Zhengzhou 12
Amsterdam 11
Central 11
Changsha 11
Florence 11
Hebei 11
Rochester 11
Athens 10
Erlangen 10
Fremont 10
Memphis 10
Pune 10
Saint Paul 10
Teresina 10
Xiamen 10
Bogotá 9
Pittsburgh 9
Verona 9
Central District 8
College Station 8
Totale 6.716
Salva come PNG Salva come JPEG
Nome #
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 675
Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario 501
Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function 480
Coming back: autophagy in cachexia 467
ß-hydroxy-ß-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia 462
Novel investigational drugs mimicking exercise for the treatment of cachexia 416
Autophagic degradation contributes to muscle wasting in cancer cachexia 412
Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency? 332
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) 269
Cytotoxic properties of clofibrate and other peroxisome proliferators: relevance to cancer progression 256
Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by Tumor Necrosis Factor-alpha 239
Changes in myostatin signaling in non weight-losing cancer patients 214
Mechanism-based therapeutic approaches to cachexia 213
Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations 211
Effect of the specific proteasome inhibitor Bortezomib on cancer-related muscle wasting 204
Molecular and cellular mechanisms of skeletal muscle atrophy: an update 201
Autophagy is induced in the skeletal muscle of cachectic cancer patients 195
Combined approach to counteract experimental cancer cachexia: eicosapentenoic acid and training exercise 193
Role of Inflammation in Muscle Homeostasis and Myogenesis 191
Vitamin D and VDR in cancer cachexia and muscle regeneration 182
New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia 168
Early changes of muscle IGF-1 and myostatin gene expression in gastric cancer patients 153
Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition 150
Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models 148
Interference with Ca 2+ -dependent proteolysis does not alter the course of muscle wasting in experimental cancer cachexia 139
CASPASE 2 ACTIVATION AND ER STRESS DRIVE RAPID JURKAT CELL APOPTOSIS BY CLOFIBRATE 138
Differences in food intake of tumour-bearing cachectic mice are associated with hypothalamic serotonin signalling 138
A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy 138
Moderate exercise improves experimental cancer cachexia by modulating the redox homeostasis 133
The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing mice 128
Modulating metabolism to improve cancer-induced muscle wasting 123
Ca(2+)-dependent proteolysis in muscle wasting. 122
The Skeletal Muscle as an Active Player Against Cancer Cachexia 120
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma 112
Animal models for cancer cachexia 105
Distinct Behaviour of Sorafenib in Experimental Cachexia-Inducing Tumours: The Role of STAT3. 103
Patogenesi dell'ipotrofia muscolare nella cachessia neoplastica: ruolo della via di segnalazione attivata da IGF-1 100
Interleukin-4 administration improves muscle function, adult myogenesis, and lifespan of colon carcinoma-bearing mice 99
Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses 98
Point mutated Caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature 95
A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan 95
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy 90
Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist 89
Ca2+-dependent apoptosis in Jurkat cells treated with clofibrate 85
Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? 81
Anticytokine strategies for the treatment of cancer-related anorexia and cachexia 80
Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice 79
Are there any benefits for exercise training in cancer cachexia? 77
Targeting mitochondria by ss-31 ameliorates the whole body energy status in cancer-and chemotherapy-induced cachexia 76
Are antioxidants useful to treat skeletal muscle atrophy? 75
Extracellular vesicles derived from tumour cells as a trigger of energy crisis in the skeletal muscle 69
L'inibizione del sistema proteolitico ATP-ubiquitina dipendente non previene la perdita di massa muscolare in un modello sperimentale di cachessia neoplastica 67
MODULATIONS OF MYOSTATIN IN CANCER CACHEXIA. 66
Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia 66
Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations 63
Protein kinases in the pathogenesis of muscle wasting 62
Combined Exercise Training Positively Affects Muscle Wasting in Tumor-bearing Mice 62
Effect of dehydroepiandrosterone in the prevention of cancer- and diabetes-induced cachexia 61
PERTURBATIONS OF THE IGF-1 SYSTEM IN CANCER CACHEXIA 59
Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia—the effects of blocking myostatin and activins 59
Myostatin blockade by deacetylase inhibitors fails to counteract muscle wasting in tumor-bearing mice 55
The redox balance: a target for interventions against muscle wasting in cancer cachexia? 54
Muscle wasting in diabetic and in tumor-bearing rats: Role of oxidative stress 52
MYOSTATIN EXPRESSION IS UPREGULATED IN CANCER CACHEXIA. 52
Nutritional support in cancer 52
Pharmacological inhibition of the ubiquitin/proteasome ATP-dependent system does not prevent muscle wasting in experimental cancer cachexia 51
MYOSTATIN PATHWAY: FROM EXPERIMENTAL CANCER CACHEXIA TO CANCER PATIENTS 50
Modulations of the calcineurin/NF-AT pathway in diabetes-induced skeletal muscle atrophy. 48
The role of Vitamin D in cancer cachexia 47
Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia 46
Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia 44
Control of skeletal muscle atrophy associated to cancer or corticosteroids by ceramide kinase 44
IGF-1 is down-regulated in experimental cancer cachexia 43
Mitochondrial dysfunction in cancer cachexia: Impact on muscle health and regeneration 43
Sarcopenia diagnosis: Reliability of the ultrasound assessment of the tibialis anterior muscle as an alternative evaluation tool 39
Mechanisms of clofibrate-induced apoptosis in Yoshida AH-130 hepatoma cells 38
Research update for articles published in EJCI in 2008 37
Muscle myostatin signaling is enhanced in experimental cancer cachexia 32
NAD+ repletion with niacin counteracts cancer cachexia 30
Glutamine and myostatin expression in muscle 29
Small non-coding RNA profiling in patients with gastrointestinal cancer 27
PGC-1α in the myofibers regulates the balance between myogenic and adipogenic progenitors affecting muscle regeneration 27
Targeting the activin receptor signaling to counteract the multi-systemic complications of cancer and its treatments 27
Targeting Mitochondria and Oxidative Stress in Cancer- and Chemotherapy-Induced Muscle Wasting 26
Amino Acids in Cancer and Cachexia: An Integrated View 26
Involvement of released sphingosine 1-phosphate/sphingosine 1-phosphate receptor axis in skeletal muscle atrophy 25
Fecal miRNA profiles and gut metagenome composition in Lynch syndrome: results from a mouse model study and human subjects 23
Exercise and Exercise Mimetics for the Treatment of Musculoskeletal Disorders 20
Extracellular Vesicles and Exosomes in the Control of the Musculoskeletal Health 19
The BET inhibitor JQ1 targets fat metabolism and counteracts obesity 19
Immunomodulation: A new approach to cancer cachexia, potentially suitable for aging 15
Totale 11.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.270
article - articoli 0
book - libri 0
conference - conferenze 2.472
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020970 0 0 0 0 0 214 172 131 162 120 95 76
2020/20211.238 75 102 114 73 118 64 93 74 89 145 78 213
2021/20221.226 59 64 73 110 90 101 71 80 64 101 194 219
2022/20231.568 170 134 88 120 145 311 132 97 165 46 81 79
2023/20241.241 133 136 96 111 116 97 93 87 37 103 100 132
2024/20251.555 90 185 136 196 672 276 0 0 0 0 0 0
Totale 11.424